ClinicalTrials.gg
CompletedNCT00891527PVSUpdated Jun 19, 2019Results posted

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis

A Phase 1/2 interventional study of Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) in Pulmonary Veno Occlusive Disease, sponsored by Boston Children's Hospital. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2019-06-19.

Sponsored by Boston Children's Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2008, registered Apr 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Sex
All
01

Study summary

The objective of this study is to conduct a pilot study using biologic agents Avastin and Gleevec to treat progression of multivessel intraluminal pulmonary vein stenosis in children.

Read the detailed description

Intraluminal pulmonary vein stenosis is rare but life threatening disease that affects both infants and children. It can be isolated to a single pulmonary vein, but most often occurs in multiple vessels simultaneously. It can occur as a complicating feature of complex congenital heart disease, but can also occur in isolation in infants with otherwise normal hearts. Response to conventional surgical or transcatheter-based therapies is usually short-lived. Typically within 3 to 4 weeks the obstruction recurs. Repeat surgical attempts provide only temporary relief and eventually all of these infants die without lung transplantation.

While the cause of this disease is unknown the mechanism of progressive obstruction has recently been determined through biopsy and autopsy reviews to result from neo-proliferative cells identified as myofibroblasts which have cell markers VEGF and PDGF. Chemotherapeutic agents Avastin and Gleevec have shown to inhibit myo-proliferation through these markers. The overall objective of this protocol is to conduct a pilot study using the biologic agents Avastin and Gleevec to treat progression of intraluminal pulmonary vein stenosis (PVS). From this pilot group of 10 patients we will attempt to provide an enhanced characterization of the progressive primary disease process, as well as its secondary manifestations. Results will be analyzed descriptively; data gathered from this pilot study will be used to inform further study examining safety and efficacy outcomes. Initial study was limited to 10 patients, but was later expanded to 50 enrolled patients.

The study objectives will be accomplished by achievement of the following Specific Aims:

  1. To describe the feasibility of administration of Gleevec® with or without Avastin® to treat the progression of intraluminal PVS in patients with multivessel disease. Patients with PVS in conjunction with congenital heart disease (CHD) will receive Gleevec® alone, with Avastin® added if significant progression occurs; patients with primary PVS and PVS in conjunction with lung disease will be treated with both drugs simultaneously.
  2. To characterize the time to progression and the proportion of patients who survive 48 weeks after enrollment.
  3. To describe the toxicity associated with administration of Gleevec® with or without Avastin® during a 48 week course of treatment among patients with multivessel PVS.

Patients will be treated with Gleevec® with or without Avastin® for a period of 48 weeks, and will be followed until 72 weeks. Clinical status will be assessed by serial lab testing, monthly echocardiography and lung scans, and baseline and q24 week CT angiography or angiography. Obstruction of individual pulmonary veins will be assessed using a standard score, and patients will be classified as stabilized, recurred or progressed based on changes in the individual vein scores.

02

Conditions studied

  • Pulmonary Veno Occlusive Disease

Keywords

  • Pulmonary Vein Stenosis,
  • Avastin and Gleevec,
  • Targeting VEGF and PDGF
03

In context

Lead sponsor

Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria: (Both groups)

  • Evidence of intraluminal pulmonary vein stenosis in > 1 vessel
  • Evidence of myofibroblast neo-proliferation, if were obtained
  • Acceptable organ function includes:

Creatinine \< 1.5 x normal for age. \< 1.5 x normal for age. \< or = 5x normal > or = 1,500/mm3, > or = 10g/dl, > or = 100,000/mm3.

Group A Eligibility Criteria: (begin treatment with Gleevec® only)

  • Significant concomitant congenital heart defect
  • Disease severity for each vessel Category 5 or lower or Category 6 or 7 in no more than 1 vessel

Group B Eligibility Criteria: (begin treatment with Gleevec® and Avastin®)

  • Primary PVS (i.e. without concomitant congenital heart defect or lung disease)
  • Significant concomitant lung disease
  • Patients with PVS and underlying CHD who have category 6 or 7 disease in at least 2 of their pulmonary veins even after surgical or cath-based interventions.
  • Accepted organ function includes:

Urine protein \< 1

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Avastin and/or Gleevec

    Patients were all treated with Gleevec (imatinib mesylate) and those without congenital heart disease and those who progressed were also treated with Avastin (bevacizumab).

    Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)

Interventions

  • DrugBevacizumab (Avastin) and Imatinib Mesylate (Gleevec)

    Drug page: BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal. Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated.

    Also known as: Bevacizumab (rhuMAb VEGF, Avastin), NSC 704865, Imatinib Mesylate (Gleevec, STI571), NSC 716051, IND 61,135

06

What researchers measure

Primary outcomes

  1. Number of Patients With Survival at 48 Weeks

    Time frame: 48 weeks

Secondary outcomes

  1. Number of Patients With Disease Progression at 48 Weeks

    Patients will be classified as having disease progression if at least 2 pulmonary veins have significantly worsened at 48 weeks. This determination is based on the study defined Pulmonary Vein Status Scale, which categorizes pulmonary veins on a scale from "1- None: No narrowing of the luminal contour," to "7- Distal atretic: Complete obliteration of the luminal contour extending \>5mm within the vessel segment."

    Time frame: 48 weeks

  2. Number of Patients With Disease Stabilization at 48 Weeks

    Time frame: 48 weeks

07

Results

Posted May 31, 2017

Participant flow

Participant flow — Overall Study
MilestoneAvastin and/or Gleevec
Started50
Completed48
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber of Patients With Survival at 48 Weeks
Time frame:
48 weeks
Reported as:
Count of participants · Participants
Number of Patients With Survival at 48 Weeks
ParticipantsAvastin and/or Gleevec
Number of Patients With Survival at 48 Weeks42
SecondaryNumber of Patients With Disease Progression at 48 Weeks

Patients will be classified as having disease progression if at least 2 pulmonary veins have significantly worsened at 48 weeks. This determination is based on the study defined Pulmonary Vein Status Scale, which categorizes pulmonary veins on a scale from "1- None: No narrowing of the luminal contour," to "7- Distal atretic: Complete obliteration of the luminal contour extending \>5mm within the vessel segment."

Time frame:
48 weeks
Reported as:
Count of participants · Participants
Number of Patients With Disease Progression at 48 Weeks
ParticipantsAvastin and/or Gleevec
Number of Patients With Disease Progression at 48 Weeks5
SecondaryNumber of Patients With Disease Stabilization at 48 Weeks
Time frame:
48 weeks
Reported as:
Count of participants · Participants
Number of Patients With Disease Stabilization at 48 Weeks
ParticipantsAvastin and/or Gleevec
Number of Patients With Disease Stabilization at 48 Weeks15

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avastin and/or Gleevec11/48 (22.9%)10/48 (20.8%)48/48 (100%)
Most frequent serious events
Most frequent serious events
EventAvastin and/or Gleevec
InfectionInfections and infestations5/48
Gastrointestinal ToxicityGastrointestinal disorders4/48
Bone Marrow SuppressionBlood and lymphatic system disorders2/48
HospitalizationGeneral disorders2/48
TremorsGeneral disorders1/48
Most frequent other events
Most frequent other events
EventAvastin and/or Gleevec
Blood Bone Marrow SuppressionBlood and lymphatic system disorders48/48
OtherGeneral disorders41/48
Liver ToxicityGeneral disorders32/48
Renal ToxicityRenal and urinary disorders31/48
Gastrointestinal ToxicityGastrointestinal disorders27/48
InfectionInfections and infestations22/48
RashSkin and subcutaneous tissue disorders13/48
TransfusionGeneral disorders6/48

Baseline characteristics

Age, Customized
Age, Customized(Participants)Avastin and/or Gleevec
<3 months3
3 to <6 months15
6 to <12 months17
>/= 12 months13
Sex: Female, Male
Sex: Female, Male(Participants)Avastin and/or Gleevec
Female21
Male27
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Avastin and/or Gleevec
08

Study locations

1 site
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
09

References and documents

Publications

  • Bini RM, Cleveland DC, Ceballos R, Bargeron LM Jr, Pacifico AD, Kirklin JW. Congenital pulmonary vein stenosis. Am J Cardiol. 1984 Aug 1;54(3):369-75. doi: 10.1016/0002-9149(84)90199-1. PubMed 6465018 ↗
  • Webber SA, de Souza E, Patterson MW. Pulsed wave and color Doppler findings in congenital pulmonary vein stenosis. Pediatr Cardiol. 1992 Apr;13(2):112-5. doi: 10.1007/BF00798218. PubMed 1614915 ↗
  • Adey CK, Soto B, Shin MS. Congenital pulmonary vein stenosis: a radiographic study. Radiology. 1986 Oct;161(1):113-7. doi: 10.1148/radiology.161.1.3763853. PubMed 3763853 ↗
  • Mendelsohn AM, Bove EL, Lupinetti FM, Crowley DC, Lloyd TR, Fedderly RT, Beekman RH 3rd. Intraoperative and percutaneous stenting of congenital pulmonary artery and vein stenosis. Circulation. 1993 Nov;88(5 Pt 2):II210-7. PubMed 8222156 ↗
  • Driscoll DJ, Hesslein PS, Mullins CE. Congenital stenosis of individual pulmonary veins: clinical spectrum and unsuccessful treatment by transvenous balloon dilation. Am J Cardiol. 1982 May;49(7):1767-72. doi: 10.1016/0002-9149(82)90257-0. PubMed 6211076 ↗
  • Bahl VK, Chandra S, Mishra S. Congenital stenosis of isolated pulmonary vein: role of retrograde pulmonary vein catheterization. Int J Cardiol. 1997 Jun 27;60(1):103-5. doi: 10.1016/s0167-5273(97)02972-0. PubMed 9209947 ↗
  • Mendeloff EN, Spray TL, Huddleston CB, Bridges ND, Canter CB, Mallory GB Jr. Lung transplantation for congenital pulmonary vein stenosis. Ann Thorac Surg. 1995 Oct;60(4):903-6; discussion 907. doi: 10.1016/0003-4975(95)00543-t. PubMed 7574992 ↗
  • Martinez-Climent J, Cavalle T, Ferris Tortajada J. Non-malignant tumors that can mimic cancer during the neonatal period. Eur J Pediatr Surg. 1995 Jun;5(3):156-9. doi: 10.1055/s-2008-1066193. PubMed 7547802 ↗
  • Herman TE, Siegel MJ. Special imaging casebook. Infantile myofibromatosis: solitary and multifocal varieties. J Perinatol. 1995 May-Jun;15(3):250-2. No abstract available. PubMed 7666279 ↗
  • Davies RS, Carty H, Pierro A. Infantile myofibromatosis--a review. Br J Radiol. 1994 Jul;67(799):619-23. doi: 10.1259/0007-1285-67-799-619. PubMed 8061994 ↗
  • Hutchinson L, Sismanis A, Ward J, Price L. Infantile myofibromatosis of the temporal bone: a case report. Am J Otol. 1991 Jan;12(1):64-6. PubMed 2012194 ↗
  • Goldberg NS, Bauer BS, Kraus H, Crussi FG, Esterly NB. Infantile myofibromatosis: a review of clinicopathology with perspectives on new treatment choices. Pediatr Dermatol. 1988 Feb;5(1):37-46. doi: 10.1111/j.1525-1470.1988.tb00882.x. PubMed 3288983 ↗
  • Duffy MT, Harris M, Hornblass A. Infantile myofibromatosis of orbital bone. A case report with computed tomography, magnetic resonance imaging, and histologic findings. Ophthalmology. 1997 Sep;104(9):1471-4. doi: 10.1016/s0161-6420(97)30114-6. PubMed 9307643 ↗
  • Coffin CM, Neilson KA, Ingels S, Frank-Gerszberg R, Dehner LP. Congenital generalized myofibromatosis: a disseminated angiocentric myofibromatosis. Pediatr Pathol Lab Med. 1995 Jul-Aug;15(4):571-87. doi: 10.3109/15513819509026993. PubMed 8597844 ↗
  • Hasegawa M, Kida S, Yamashima T, Yamashita J, Takakuwa S. Multicentric infantile myofibromatosis in the cranium: case report. Neurosurgery. 1995 Jun;36(6):1200-3. doi: 10.1227/00006123-199506000-00023. PubMed 7644004 ↗
  • Coffin CM, Dehner LP. Fibroblastic-myofibroblastic tumors in children and adolescents: a clinicopathologic study of 108 examples in 103 patients. Pediatr Pathol. 1991 Jul-Aug;11(4):569-88. doi: 10.3109/15513819109064791. PubMed 1946077 ↗
  • Stenzel P, Fitterer S. Gastrointestinal multicentric infantile myofibromatosis: characteristic histology on rectal biopsy. Am J Gastroenterol. 1989 Sep;84(9):1115-9. PubMed 2672792 ↗
  • Weyl Ben Arush M, Meller I, Moses M, Klausner J, Isakov J, Kuten A, el Hassid R. Multifocal desmoid tumor in childhood: report of two cases and review of the literature. Pediatr Hematol Oncol. 1998 Jan-Feb;15(1):55-61. doi: 10.3109/08880019809009508. PubMed 9509506 ↗
  • Riedlinger WF, Juraszek AL, Jenkins KJ, Nugent AW, Balasubramanian S, Calicchio ML, Kieran MW, Collins T. Pulmonary vein stenosis: expression of receptor tyrosine kinases by lesional cells. Cardiovasc Pathol. 2006 Mar-Apr;15(2):91-9. doi: 10.1016/j.carpath.2005.11.006. PubMed 16533697 ↗
  • Sadr IM, Tan PE, Kieran MW, Jenkins KJ. Mechanism of pulmonary vein stenosis in infants with normally connected veins. Am J Cardiol. 2000 Sep 1;86(5):577-9, A10. doi: 10.1016/s0002-9149(00)01022-5. PubMed 11009286 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2008 to primary completion in Dec 2015, 86 months.

Results were first posted in May 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2009
First posted
May 1, 2009
StartActual
Oct 2008
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
May 31, 2017
Last update
Jun 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00891527
Responsible party
Kathy Jenkins (Kathy J. Jenkins, MD, MPH, Boston Children's Hospital) — Principal investigator
First posted
May 1, 2009
Start date
Oct 2008
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
May 31, 2017
Last update
Jun 19, 2019

Study contacts

Kathy J Jenkins, MD, MPH
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion